The liver in systemic disease: Sepsis and critical illness
William Bernal – 27 April 2016
Transjugular intrahepatic portosystemic shunt for refractory ascites in patients with high model for end‐stage liver disease scores
Kavish R. Patidar, Arun J. Sanyal – 27 April 2016
Cryptogenic cirrhosis: Current knowledge and future directions
Alex Mercado‐Irizarry, Esther A. Torres – 27 April 2016
Reply
Guadalupe Garcia‐Tsao, Jordan Sack – 26 April 2016
Reply
Sudeep Banerjee, Michael D. Kuo – 26 April 2016
Statins in Cirrhosis: The Magic Pill?
Giuseppe Malizia, Gennaro D'Amico – 26 April 2016
Reply
Robert S. Brown, Brian J. McMahon, Anna S.F. Lok, John B. Wong, Ahmed T. Ahmed, Mohamad A. Mouchli, Zhen Wang, Larry J. Prokop, Mohammad Hassan Murad, Khaled Mohammed – 26 April 2016
Aquaporin gene therapy for disorders of cholestasis?
Lukmanee Tradtrantip, Alan S. Verkman – 26 April 2016
Author Checklist
26 April 2016
The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor‐β1 biliary secretion in mice
Nan Wu, Fanyin Meng, Pietro Invernizzi, Francesca Bernuzzi, Julie Venter, Holly Standeford, Paolo Onori, Marco Marzioni, Domenico Alvaro, Antonio Franchitto, Eugenio Gaudio, Shannon Glaser, Gianfranco Alpini – 26 April 2016 – The secretin/secretin receptor (SR) axis is up‐regulated by proliferating cholangiocytes during cholestasis. Secretin stimulates biliary proliferation by down‐regulation of let‐7a and subsequent up‐regulation of the growth‐promoting factor, nerve growth factor (NGF).